Nikhil C. Munshi, MD
Harvard Medical School
Associate Professor, Medical Oncology
Dana-Farber Cancer Institute
Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University and Shri Sayaji General Hospital in Baroda, India. He completed a medical oncology research fellowship at Johns Hopkins Oncology Center before receiving a clinical fellowship in hematology/oncology at Indiana University Medical Center. Dr. Munshi is Professor of Medicine at Harvard Medical School, the Director of Basic and Correlative Science, and Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute. In addition, he is an attending physician at the Brigham and Women’s Hospital and the Boston VA Healthcare System, Harvard Medical School.
Dr. Munshi has organized and chaired numerous guideline panels to develop consensus recommendations for management of myeloma. He serves as a co-chair of the National Steering Committee on Myeloma (National Cancer Institute), is member of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee, and is a founding member and vice-president of the International Myeloma Society. Dr. Munshi has written more than 400 peer-reviewed publications and has contributed chapters on plasma cell neoplasms in Harrison’s Principles of Internal Medicine; DeVita’s Principles and Practice of Oncology, and Hoffman’s Hematology: Basic Principles and Practice. He received a Leukemia Society of America Scholar in Translational Research and the Waldenström’s Award for the most Distinguished Lifetime Achievement in Myeloma Research in 2013.
A recognized international leader in translational research in multiple myeloma, Dr. Munshi’s focus spans both basic sciences to understand molecular mechanisms driving the genomic instability to translational approaches directed at improving diagnosis and prognosis, as well as therapeutics including novel antigen-directed immunotherapy/vaccine approaches and small molecules for myeloma. His research has provided pivotal understanding of genomic changes in myeloma.